• A background image for the homepage link to information on Pradaxa's (Dabigatran) reversal agent
    More control – Pradaxa now has a specific, immediate reversal agent
  • A background image for the homepage link to the 'confidence from extensive clinical data' page
    Favorable benefit-risk profile with Pradaxa
    More than 6 years of clinical safety and efficacy data with RE-LY® and RELY-ABLE® combined.2-5
  • A background image for the homepage link to the 'real world evidence for Pradaxa (Dabigatran)' page
    A new level of confidence in anticoagulation care – extensive real-world data for Pradaxa
    Safety and effectiveness validated by independent authorities including the FDA.6-12
  • A background image for the homepage link to the page on Pradaxa's (Dabigatran) indications
    Confidence across a range of indications
    Pradaxa has 7 current approved uses for treatment and prevention.13
  • A background image for 'prescribing Pradaxa (Dabigatran) in non-valvular atrial fibrillation (NVAF)'
    Pradaxa offers prescribing flexibility
    With Pradaxa you have the confidence of two fully studied doses.4
  • Image: the 'dosing of Pradaxa (Dabigatran) in non-valvular atrial fibrillation (NVAF)' page
    Pradaxa dosing
    Simple, straightforward administration, regardless of indication.13
  • A background image for the homepage link to the Praxbind (Idarucizumab) page
    A new standard in anticoagulation care
    Together, Pradaxa with Praxbind provide a new standard in anticoagulation care.
References: 
  1. Praxbind Summary of Product Characteristics 2015. Boehringer Ingelheim.
  2. Connolly SJ et al. N Engl J Med 2009;361(12):1139–1151.
  3. Connolly SJ et al. N Engl J Med 2010;363(19):1875–1876 (appendix).
  4. Connolly SJ et al. N Engl J Med 2014:371(15):1464–1465.
  5. Connolly SJ et al. Circulation 2013;128(3):237-243.
  6. Graham DJ et al. Circulation 2015;131(2):157–164.
  7. Seeger JD et al. Presented at AHA 2014.
  8. Villines TC et al. Presented at AHA 2014.
  9. Larsen TB et al. Am J Med 2014;127(7):650–656.e5.
  10. Larsen TB et al. Am J Med 2014;127(4):329–336.e4.
  11. Lauffenburger JC et al. J Am Heart Assoc 2015;4(4):e001798.
  12. Abraham NS et al. BMJ 2015;350:h1857.
  13. Pradaxa Summary of Product Characteristics 2015. Boehringer Ingelheim.